Lung (includes NSCLC, SCLC, Mesothelioma)

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy

(Merck) June 18, 2019 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. This accelerated approval is based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. This marks the first indication for KEYTRUDA in SCLC.

read corporate press release

FDA Approves Pembrolizumab For Metastatic Small Cell Lung Cancer

(FDA.gov) June 18, 2019 - On June 17, 2019, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. Efficacy was investigated in 83 patients with SCLC who had disease progression on or after two or more prior lines of therapy enrolled in one of two multicenter, multi-cohort, non-randomized, open label trials: KEYNOTE-158 (NCT02628067) Cohort G or KEYNOTE-028 (NCT02054806) Cohort C1.

read press release

Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer

(Associated Press) June 18, 2019 - Jounce Therapeutics, Inc. today announced that it has initiated dosing in the Phase 2 EMERGE clinical trial of its lead product candidate, vopratelimab, in combination with ipilimumab in patients with non-small cell lung cancer (NSCLC) or urothelial cancer who have progressed on or after PD-1/PD-L1 inhibitor therapies.

read article

FDA Action Alert: Merck, Agios and AMAG Pharma

(BioSpace) June 17, 2019 - June is turning out to be a busy month for approvals for the U.S. Food and Drug Administration (FDA). The agency has a slate of PDUFA dates this week, including two for Merck alone. Here’s a look.

read article

Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial

(Immutep) June 13, 2019 - Recruitment for 2nd line (PD-1 refractory) NSCLC and 2nd line HNSCC cohorts of the TACTI-002 trial, conducted in collaboration with MSD, are ongoing.

read corporate press release

Next Up For KRAS-Blocking Cancer Drug Fans: A Hugely Important Data Reveal From Mirati Therapeutics

(STAT Plus) June 12, 2019 - After the impressive tumor-shrinking data shown by Amgen from its KRAS-targeted cancer drug at the recently completed ASCO meeting, attention — and pressure — now shift to Mirati Therapeutics and its competing KRAS blocker.

read article (paid subscription required)

Radiation Treatment Increases Cardiac Risk for Lung Cancer Patients

(BWH) June 10, 2019 - A new retrospective study led by investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute examined outcomes for patients after receiving treatment for locally advanced NSCLC, finding that the average radiation dose delivered to the heart was associated with an increased risk of major adverse cardiovascular events and death.

read press release

Association of Community Cancer Centers Collaborates with AstraZeneca to Launch National Initiative to Support Quality Care Initiative for Stage III and IV Non-Small Cell Lung Cancer

(ACCC) June 11, 2019 - The Association of Community Cancer Centers (ACCC) is pleased to announce it is collaborating with AstraZeneca, a global, science-led biopharmaceutical company to support a national quality care initiative for patients with stage III and stage IV non-small cell lung cancer (NSCLC).

read press release

Study: Race Could Be A Determinant In Physician-Patient Interactions And Pain Treatment In Cancer

(Purdue University) June 3, 2019 - A 62-year-old with stage IV lung cancer that has spread to his bones, causing unspeakable pain, is trying to convince his physician to prescribe pain medicine. What happens next?

read press release

Opinion: Iovance and Amgen Are Making Cancer History

(Washington Post/Bloomberg) June 5, 2019 - The annual meeting of the American Society of Clinical Oncology (ASCO), which wrapped up Tuesday, is one of the drug industry’s most prominent platforms for showcasing promising cancer research and treatments. This year was no exception.

read article (free registration required)

ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More

(Xconomy National) June 5, 2019 - The American Society of Clinical Oncology meeting in Chicago has wrapped up for another year.

read article

ASCO Updates: RemeGen, Genentech, Johnson & Johnson, Bristol-Myers Squibb and Bayer

(BioSpace) June 4, 2019 - As the American Society of Clinical Oncology (ASCO) Annual Meeting winds down, here’s a look at some of Monday’s top stories.

read article

At ASCO, Targeted Lung Cancer Drugs Shrink Tumors Caused By Rare Genetic Mutations

(STAT Plus) June 3, 2019 - Precision medicine in lung cancer is making a big impact at this year’s ASCO meeting. Rare mutations in lung tumors discovered through genetic screening are leading to the development of highly targeted drugs. And these drugs are shrinking tumors in patients not helped by current treatments. Two case studies: A drug called BLU-667 from the biotech Blueprint Medicines caused tumors to shrink in 60% of patients with lung tumors containing an alteration to a gene called RET. These patients entered the clinical trial after standard chemotherapy stopped working.

read article (paid subscription required)

Atara Biotherapeutics Announces Collaborator Presentation Updating Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma

(Associated Press) June 4, 2019 - Atara Biotherapeutics, Inc. today announced that the Company’s collaborators at Memorial Sloan Kettering Cancer Center (MSK), Prasad S. Adusumilli, M.D. and Michel Sadelain, M.D., Ph.D., presented an update on encouraging results from an ongoing MSK investigator-sponsored Phase 1 clinical study ( NCT02414269 ) of a mesothelin-targeted CAR T immunotherapy for patients with mesothelin-associated malignant pleural solid tumors, primarily mesothelioma, who progressed following platinum-containing chemotherapy.

read article

ASCO 2019 – Tepotinib And Capmatinib Fight Over A New Lung Cancer Niche

(Vantage) June 4, 2019 - cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.

read article

How Real-World Data Can Impact NSCLC Treatment

(AJMC Managed Markets Network) June 4, 2019 - A number of abstracts at the 2019 American Society of Clinical Oncology Annual Meeting, held May 31 to June 4, 2019, in Chicago, Illinois, featured studies that focused on using real-world data to advance research and cancer care in non–small cell lung cancer (NSCLC).

read article

Early Cancer Drug Data Give Amgen Hope It Has 'Cracked KRAS Code'

(BioPharma Dive) June 3, 2019 - Decades of research have failed to uncover a therapeutic answer to one of the most well-known genetic drivers of cancer. Yet Amgen thinks it's broken through with an early-stage drug that, in initial results presented Monday at the American Society of Clinical Oncology's annual meeting, spurred tumors to shrink in five of 10 lung cancer patients. The therapy's target is KRAS, an oncogene known to be behind many lung, pancreatic and colorectal cancers. Past efforts to develop an effective treatment have consistently come up short — a history that makes Amgen's data noteworthy despite coming from just a handful of patients.

read article

Drugs Make Headway Against Lung, Breast, Prostate Cancers

(Minneapolis Star Tribune/AP) June 2, 2019 — Newer drugs are substantially improving the chances of survival for some people with hard-to-treat forms of lung, breast and prostate cancer, doctors reported at the world’s largest cancer conference.

read article

Blueprint Keeps Pressure On Lilly With RET-Targeted Cancer Therapy

(BioPharma Dive) June 3, 2019 - Updated clinical data showed Blueprint Medicine's targeted cancer drug for RET-mutated lung and thyroid cancers caused tumors to shrink in roughly three-fifths of patients, supporting the biotech's plans to file for regulatory approval in the U.S. early next year.

read article

Final Progression-Free Survival Data and the Second Interim Analysis of Overall Survival from the J-ALEX Study for Alecensa Presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

(Chugai Pharmaceutical) June 3, 2019 - Alecensa reduced the risk of disease progression or death by 63% compared to crizotinib. Long-term follow-up reconfirmed that Alecensa prolonged progression-free survival compared to crizotinib.

read corporate press release
Next Page